Allergan (AGN) August weekly volatility flat into Q2 and outlook

Go back to Allergan (AGN) August weekly volatility flat into Q2 and outlook

Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q

August 9, 2016 9:08 AM EDT

Piper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.

Analyst David Amsellem commented, "Allergan... More

Allergan (AGN) Tops Q2 EPS by 1c

August 8, 2016 7:02 AM EDT

Allergan (NYSE: AGN) reported Q2 EPS of $3.35, $0.01 better than the analyst estimate of $3.34. Revenue for the quarter came in at $3.68 billion versus the consensus estimate of $4.1 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

... More